AI
Clinical
Research

Our expertise

Our team of professionals have expertise in phase I-IV clinical trials, many of them being registrational studies.

All are equipped according to legislation requirements and operated by qualified healthcare professionals who oversee subject safety and ensure study conduct.

THE IMPACT OF OUR WORK

AICR personnel was previously involved in CTs resulting in the following medicinal products, only mentioning the brand names:

Cardiovascular DiseasesTekturna®, Entresto®, Corlanor®, Brilique®, Crestor®
Diabetes, Obesity and  Metabolic disordersGalvus®, Eucreas®, Victoza®, Saxenda®, Ozempic®, Rybelsus®, Wegovy®, Farxiga®, Xigduo®, Onglyza®, Glucophage®
Cagrisema® – Investigational, Obesity
BYM 338 – bimagrumab – Investigational, currently in obesity
OncologyLeukeran®, Tarceva®, Sutent®, Imfinzi®, Taxol®, Faslodex®, Zoladex®, Tagrisso®, Arimidex®, Lynparza®
Tremelimumab – Investigational, no brand name
Cilta cell + DVR – Investigational in oncology, no brand name
Respiratory DiseasesArcapta® Neohaler, Onbrez® Breezhaler, Seebri® Breezhaler, Lonhala Magnair®, Nasonex®, Astelin®, Astepro®, Symbicort®, Pulmicort®, Fasenra®
Fevipiprant – Investigational, asthma, CDP stopped
Neurological disorders and PsychiatryGilenya®, Mayzent®, Aubagio®, Copaxone®, Azilect®, Tegretol®, Risperdal®, Abilify®, Seroquel®
Laquinimod – Investigational, no brand name
Tolebrutinib – Investigational, for multiple sclerosis
Gastrointestinal DisordersProtonix®, Losec®, Nexium®
Reproductive HealthMifeprex®, Makena®
Anti-infective and VaccinesSebivo®, Synagis®, Varivax®
Autoimmune Diseases and Inflammatory DisordersIlaris®, Cosentyx®, Actemra®, Skyrizi®, Vimovo®, Xolair®
Antiflorumab – Investigational, no brand name
IMU-838 – Under investigation, no brand name
Tozorakimab – Investigational, no brand name
Miscellaneous / InvestigationalSBR157 – Investigational, CDP stopped, CKD dyalisis patients
Recombinant Human G-CSF hyFc – Investigational, for enhancing white blood cell count
×